20 December 2024
VALIRX PLC
("ValiRx"
or the "Company")
ValiRx launches new
interactive investor website
providing shareholders with a
more proactive way of communication and enquiry
support
ValiRx, a life science company
focusing on early-stage cancer therapeutics and women's health, is
pleased to announce the launch of our interactive investor
website.
For both existing and prospective
shareholders, the new investor hub brings all ValiRx content into a
single integrated platform to better inform and engage with
investors and stakeholders, including:
● Regulatory
announcements
●
Reports
●
Presentations
●
Educational material
●
Interviews
● Corporate
research
The investor hub also provides an
interactive online experience allowing ValiRx stakeholders to
comment on and ask the ValiRx team questions via a portal which
will be monitored and responded to in a timely manner.
The Company's AIM Rule 26 website
address and all information required by AIM Rule 26 remains
unchanged.
How
to sign up for the ValiRx investor hub:
1. Visit
www.valirx.com
2. Follow the
prompts to sign up for an investor hub account
3. Complete your
account profile
Mark Eccleston, CEO, commented:
"As a life sciences company focused on advancing cutting-edge
therapies, it is essential that we keep our shareholders informed
and engaged throughout our journey. InvestorHub enables us to
identify and understand our investor base more clearly, allowing us
to tailor communications that highlight key milestones, clinical
developments, and the value of our progress. This ensures our
shareholders remain aligned with our mission to deliver innovative
solutions in healthcare."
Ends
Engage with the ValiRx management
team directly by asking questions, watching
video
summaries and
seeing what other shareholders have to say. Navigate to our
Interactive Investor
hub here: https://valirx.com/s/cc8ef3
The Directors are responsible for the
release of this announcement.
For
further information, please contact:
|
Investor questions on this announcement
We encourage all investors to share
questions
on this announcement via our
investor hub
|
https://valirx.com/link/vPn48e
|
|
ValiRx plc
Dr Mark Eccleston, CEO
|
Tel: +44 (0) 2476 796496
www.valirx.com
Mark.Eccleston@valirx.com
|
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0) 20 7186 9000
|
|
V
Formation (Public Relations)
Lucy Wharton - Senior PR
Executive
Sue Carr - Director
|
+44
(0) 115 787 0206
www.vformation.biz
lucy@vformation.biz
sue@vformation.biz
|
Subscribe to our news alert service:
https://valirx.com/s/f298d1
This communication is a "Reach"
announcement. Reach is a non-regulatory news service. By using this
service an issuer is confirming that the information contained in
this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.